| # | Title | Journal | Year | Citations |
|---|
| 1 | The global NAFLD epidemic | Nature Reviews Gastroenterology and Hepatology | 2013 | 1,426 |
| 2 | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target | American Journal of Gastroenterology | 2015 | 1,425 |
| 3 | Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis | Gastroenterology | 2012 | 1,062 |
| 4 | STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD | Gastroenterology | 2021 | 1,054 |
| 5 | Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease | New England Journal of Medicine | 2012 | 984 |
| 6 | Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease | Gastroenterology | 2019 | 882 |
| 7 | NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria | Cell | 2016 | 859 |
| 8 | Mechanisms and disease consequences of nonalcoholic fatty liver disease | Cell | 2021 | 757 |
| 9 | Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis | Gastroenterology | 2014 | 753 |
| 10 | Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis | New England Journal of Medicine | 2012 | 716 |
| 11 | Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry | American Journal of Gastroenterology | 2012 | 652 |
| 12 | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | Lancet, The | 2017 | 633 |
| 13 | The safety of vedolizumab for ulcerative colitis and Crohn's disease | Gut | 2017 | 630 |
| 14 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed | Gastroenterology | 2014 | 607 |
| 15 | Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis | Gastroenterology | 2014 | 605 |
| 16 | A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis | Hepatology | 2018 | 528 |
| 17 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing | Clinical Pharmacology and Therapeutics | 2011 | 504 |
| 18 | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) | Gut | 2012 | 463 |
| 19 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions | Gastroenterology | 2017 | 442 |
| 20 | Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms | Clinical Pharmacology and Therapeutics | 2012 | 432 |
| 21 | Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis | Hepatology | 2012 | 406 |
| 22 | Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver | Gastroenterology | 1995 | 388 |
| 23 | Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study | Hepatology | 2014 | 388 |
| 24 | Crohn's disease complicated by strictures: a systematic review | Gut | 2013 | 379 |
| 25 | SAFETY Study: Alanine Aminotransferase Cutoff Values Are Set Too High for Reliable Detection of Pediatric Chronic Liver Disease | Gastroenterology | 2010 | 377 |
| 26 | Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review | American Journal of Gastroenterology | 2011 | 362 |
| 27 | Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut | Journal of Physiology | 2012 | 361 |
| 28 | Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity | Gastroenterology | 2013 | 354 |
| 29 | p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells | Cancer Cell | 2016 | 353 |
| 30 | The bile acid TGR5 membrane receptor: From basic research to clinical application | Digestive and Liver Disease | 2014 | 340 |
| 31 | Integrin-based therapeutics: biological basis, clinical use and new drugs | Nature Reviews Drug Discovery | 2016 | 324 |
| 32 | Global chemical effects of the microbiome include new bile-acid conjugations | Nature | 2020 | 316 |
| 33 | Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions | Clinical Gastroenterology and Hepatology | 2016 | 309 |
| 34 | Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis | Gastroenterology | 2017 | 307 |
| 35 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update | Clinical Pharmacology and Therapeutics | 2013 | 304 |
| 36 | Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review | Clinical Gastroenterology and Hepatology | 2018 | 299 |
| 37 | Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) | Hepatology | 2015 | 296 |
| 38 | Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study | Gastroenterology | 2015 | 294 |
| 39 | Interleukin 37 expression protects mice from colitis | Proceedings of the National Academy of Sciences of the United States of America | 2011 | 289 |
| 40 | The stomach in health and disease | Gut | 2015 | 283 |
| 41 | Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis | Gastroenterology | 2014 | 280 |
| 42 | Helicobacter pylori Infection | New England Journal of Medicine | 2019 | 277 |
| 43 | MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice | Journal of Hepatology | 2016 | 275 |
| 44 | Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials | Gut | 2017 | 274 |
| 45 | Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes | Nature Reviews Gastroenterology and Hepatology | 2017 | 272 |
| 46 | Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial | Journal of Hepatology | 2016 | 264 |
| 47 | Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis | Alimentary Pharmacology and Therapeutics | 2012 | 258 |
| 48 | The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium | American Journal of Gastroenterology | 2016 | 257 |
| 49 | A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease | Clinical Gastroenterology and Hepatology | 2014 | 256 |
| 50 | Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis | Hepatology | 2018 | 250 |
